Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...

Rhythm Pharmaceuticals (RYTM) has disclosed a new risk, in the Share Price & Shareholder Rights category. Rhythm Pharmaceuticals faces a business ...

Rhythm Pharmaceuticals, Inc. BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...

Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on ...

Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living ...